2021
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNAFLD fibrosis scoreCardiorenal outcomesFibrosis riskEMPA-REG OUTCOMELiver fat contentRisk of steatosisEffect of empagliflozinFatty liver diseaseType 2 diabetesCause deathDaily empagliflozinSteatosis indexHeart failureFibrosis scoreLiver diseaseCox regressionCardiovascular diseaseHigh riskEmpagliflozinPlaceboSteatosisRisk categoriesBaselineMeasures analysis790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME
INZUCCHI S, WANNER C, FITCHETT D, ZINMAN B, ANKER S, MATTHEUS M, VEDIN O, HANTEL S, LUND S. 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME. Diabetes 2021, 70 DOI: 10.2337/db21-790-p.Peer-Reviewed Original ResearchCardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME
Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.Peer-Reviewed Original ResearchEmpagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME
Hamilton A, Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Mattheus M, Vedin O, Hantel S, Lund S. Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME. Heart Lung And Circulation 2021, 30: s221-s222. DOI: 10.1016/j.hlc.2021.06.281.Peer-Reviewed Original Research
2020
1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.Peer-Reviewed Original ResearchObstructive sleep apneaNew-onset obstructive sleep apneaCardiovascular diseaseDohme Corp.Novo Nordisk A/SMundipharma InternationalMerck SharpEli LillyEMPA-REG OUTCOMEIncident obstructive sleep apneaFavorable metabolic effectsSanofi-AventisSystolic blood pressureCoronary artery diseaseType 2 diabetesAdvisory PanelEMPA-REGOSA statusPhilips RespironicsSanofi GenzymeSevere obesityArtery diseaseBlood pressureWaist circumferenceSleep apnea131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects
INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.Peer-Reviewed Original ResearchBoehringer Ingelheim-LillyCV deathBoehringer Ingelheim PharmaceuticalsMundipharma InternationalBaseline characteristicsNovo Nordisk A/SJanssen PharmaceuticalsEli LillyRisk reductionEMPA-REG OUTCOMEKDIGO risk categoriesPredictive baseline factorsRenal hemodynamic effectsSerious adverse eventsAdvanced kidney diseaseAdvisory PanelGlomerular filtration rateJanssen Scientific AffairsMultivariate logistic regressionDeath risk reductionNovo NordiskDiuretic therapyEGFR declineSanofi GenzymeCV disease30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.Peer-Reviewed Original ResearchInsulin-naïve patientsInsulin useBackground glucose-lowering therapyEMPA-REG OUTCOMEInsulin dose increasesInsulin-treated patientsGlucose-lowering therapyEmpagliflozin 10T2D durationInsulin doseT2D diagnosisInsulin needsPlaceboPatientsWeight gainKey covariatesDose increaseInsulinTreatment effectsNew initiationHypoglycemiaT2DTherapyYrDiagnosis28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.Peer-Reviewed Original ResearchCV deathEMPA-REG OUTCOMEAtherosclerotic cardiovascular diseaseHazard ratioNovo Nordisk A/SJanssen PharmaceuticalsBristol-Myers SquibbTreatment initiationEli LillyEMPA-REG OUTCOME trialCox proportional hazards modelAdvisory PanelBenefits of empagliflozinRisk of HHFRisk of hospitalizationNumber of patientsType 2 diabetesProportional hazards modelCumulative incidence curvesNovartis Pharmaceuticals CorporationPost Hoc AnalysisBayer AGBoehringer Ingelheim PharmaceuticalsEmpagliflozin 10Empagliflozin doses
2019
URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME
Verma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.Peer-Reviewed Original Research159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.Peer-Reviewed Original ResearchRisk factor goalsCV deathDohme Corp.Boehringer Ingelheim PharmaceuticalsNovo Nordisk A/SJanssen PharmaceuticalsMerck SharpTakeda Pharmaceutical Company LimitedHazard ratioRisk factorsNovartis AGEli LillyACE inhibitor/ARB useCV risk factor controlConsistent cardiovascular benefitEMPA-REG OUTCOMECV risk factorsRisk factor controlPfizer Inc.Sanofi-AventisNon-smoking statusAdvisory PanelPost Hoc AnalysisCV risk increasesARB use
2018
SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL
Ruggenenti P, Inzucchi S, Zinman B, Hantel S, Koitka-Weber A, von Eynatten M, Wanner C. SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. Nephrology Dialysis Transplantation 2018, 33: i487-i487. DOI: 10.1093/ndt/gfy104.sp415.Peer-Reviewed Original Research
2017
CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
Inzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.Peer-Reviewed Original Research
2016
LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE
Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.Peer-Reviewed Original ResearchHeart failure hospitalizationHigh cardiovascular riskCardiovascular deathFailure hospitalizationHeart failureStandard of careType 2 diabetesEmpagliflozin groupCardiovascular riskMajor adverse cardiovascular eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEAdverse cardiovascular eventsEffect of empagliflozinHeart failure outcomesMedian observation timeRisk of hospitalizationCardiovascular eventsPlacebo groupAdverse eventsEffect of ageOutcome trialsSafety profileMean ageBaseline age